-10% IASLC Thoracic Oncology

IASLC Thoracic Oncology
Harvey Pass, David Ball, Giorgio Scagliotti

  • Εκδόσεις: Elsevier
  • Κωδικός Προϊόντος: 9780323523578
  • Ημ. Έκδοσης: 2017/06
  • Σελίδες: 704
  • ISBN: 9780323523578
  • Έκδοση:
  • Διαθεσιμότητα: 9 - 12 ημέρες
  • 172,00€
  • 191,00€
  • Χωρίς ΦΠΑ: 172,00€
Περιλαμβάνεται ΦΠΑ 6%
Global experts, in conjunction with the International Association for the Study of Lung Cancer, bring you up to date with today’s best approaches to lung cancer diagnosis, treatment, and follow-up. IASLC Thoracic Oncology, 2nd Edition, keeps you abreast of the entire scope of this fast-changing field, from epidemiology to diagnosis to treatment to advocacy. Written in a straightforward, practical style for the busy clinician, this comprehensive, multidisciplinary title is a must-have for anyone involved in the care of patients with lung cancer and other thoracic malignancies.
Features:
  • Offers practical, relevant coverage of basic science, epidemiology, pulmonology, medical and radiation oncology, surgery, pathology, palliative care, nursing, and advocacy.
  • Provides authoritative guidance from the IASLC - the only global organization dedicated to the study of lung cancer.
New To This Edition:

  • Includes new content on molecular testing, immunotherapy, early detection, staging and the IASLC staging system, surgical resection for stage I and stage II lung cancer, and stem cells in lung cancer.
  • Features a new full-color design throughout, as well as updated diagnostic algorithms.
  • Expert Consult™ eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, Q&As, and references from the book on a variety of devices.
  • Weight: 1,950.00 grams Pages: 704 Illus: Approx. 530 illustrations (530 in full color) Size:  222 X 281 mm Product Type: Hardcover

Section 1: Lung Cancer Control and Epidemiology

1. Classical Epidemiology

2. Tobacco Control and Primary Prevention

3. Tobacco Cessation

4. Non-Smoking Related Lung Cancer

5. Gender-Related Differences in Lung Cancer

6. Genetic Susceptibility to Lung Cancer

7. Early Detection and Radiologic Screening

8. Preclinical Biomarkers for The Early Detection of Lung Cancer

9. Chemoprevention of Lung Cancer: Present and Developing Technologies

Section 2: Lung Cancer Molecular Carcinogenesis

10. Copy Number Abnormalities and Gene Rearrangements in Lung Cancer: Present and Developing Technologies

11. Mutational Events in Lung Cancer: Present and Developing Technologies

12. Epigenetic Events, Alterations, and Remodeling in Lung Cancer: Present and Developing Technologies

13. Stem Cells and Lung Cancer: In Vitro and In Vivo Studies

14. Microenvironment and Lung Cancer

15. MicroRNAs as Biomarkers for Lung Cancer

Section 3: Immunology

16. Humoral and Cellular Immune Dysregulation and Lung Cancer

Section 4: Pathology

17. Classic Anatomic Pathology and Lung Cancer

18. Molecular Testing and Lung Cancer

19. Management of the Small Biopsy in the Molecular Er

Section 5: Clinical and Radiologic Presentation of Lung Cancer

20. Clinical Presentation

21. Conventional Imaging Lung Cancer

22. PET Imaging of Lung Cancer

Section 6: Diagnosis and Staging of Lung Cancer

23. Diagnostic Work-Up of Suspected Lung Cancer

24. Surgical Staging of the Mediastinum including Mediastinoscopy and Thoracoscopy, Preoperative and Intraoperative

25. The 8th Edition of the Tumor, Node and Metastasis Classification of Lung Cancer

Section 7: Surgical Management of Lung Cancer

26. Preoperative Functional Evaluation of the Surgical Candidate

27. Results of Video Assisted Techniques for Resection of Lung Cancer

28. Results of Robotic Techniques for Resection of Lung Cancer

29. Extent of Surgical Resection for Stage I and II Lung Cancer

30. Extended Resections for Lung Cancer: Chest Wall and Pancoast Tumors

31. Extended Resections for Lung Cancer: Broncho/Vascular Sleeve Resections

32. Multiple Nodules: Management of the Patient with Synchronous or Metachronous Lung Cancers

33. Surgical Management of the Marginally Resectable Patient

Section 8: Radiotherapeutic Management of Lung Cancer

34. Technical Requirements for Lung Cancer Radiotherapy

35. Radiobiology of Lung Cancer

36. Patient Selection for Radiotherapy

37. Stage I Non-Small Cell Lung Cancer and Oligometastatic Disease

38. Ablation Options for Localized Lung Cancer

39. Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer, including Combined Modality

40. Radiotherapy in the Management of Small Cell Lung Cancer: Thoracic Radiotherapy, Prophylactic Cranial Irradiation

41. Palliative Radiotherapy for Lung Cancer: Locoregional and Metastatic

42. Acute and Late Toxicities of Thoracic Radiotherapy: Pulmonary, Esophagus, Heart

43. Treatment-Related Neurotoxicity, Medical and Radiation Therapy

Section 9: Chemotherapy and Targeted Agents for Lung Cancer

44. Front-Line Systemic Options in Non-Small Cell Lung Cancer

45. Systemic Options in Second Line and Beyond

46. Maintenance Therapy in NSCLC

47. Pharmacogenomics and Lung Cancer

48. New Targetable Pathways in Lung Cancer

49. Management of Toxicities of Targeted Therapies

50. Immunotherapy and Lung Cancer

51. Systemic Therapy in Early-Stage NSCLC

52. Treatment of Small-Cell Lung Cancer

Section 10: Other Thoracic Malignancies

53. Malignant Mesothelioma

54. Mediastinal Tumors

55. Neuroendocrine Tumors of the Lung Other than SCLC

56. Thymic Cancer/Thymoma

Section 11: Symptom Management and Complications

57. Lung Cancer Emergencies

58. Role of Palliative Care in Lung Cancer

Section 12: Clinical Trials

59. Methodology of Clinical Trials in Lung Cancer

60. How to Promote and Organize Clinical Research in Lung Cancer

Section 13: Thoracic Oncology Advocacy

61. Role of Advocacy Groups in Lung Cancer

62. Health Services Research in Lung Cancer

Appendix

63. Appendix: Diagnostic Algorithms

Γράψτε μια αξιολόγηση

Παρακαλώ συνδεθείτε ή δημιουργήστε λογαριασμό για να αξιολογήσετε
Loading...